Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways.
BACKGROUND/AIM
Activation of AKT serine/ threonine kinase (AKT) predicts poor outcome in neuroblastoma, which highlights the potential of the AKT pathway as a promising target for neuroblastoma treatment. Several studies reported that blockade of α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptors (AMPARs) reduces proliferation in glioblastoma or lung cancer by inhibiting AKT and extracellular signal-related kinase (ERK) pathways. In this study, we examined the effect of the AMPAR antagonist perampanel on human neuroblastoma cells.


MATERIALS AND METHODS
Cell proliferation, caspase activity, and western blot assays were performed to determine the effect of perampanel on the KP-N-SI9s human neuroblastoma cell line.


RESULTS
Perampanel inhibited cell proliferation without triggering apoptosis in neuroblastoma cells. Down-regulation of AKT protein levels, AKT phosphorylation, and ERK1/2 phosphorylation were also observed in neuroblastoma cells with perampanel treatment.


CONCLUSION
Perampanel inhibits neuroblastoma cell proliferation through down-regulation of AKT and ERK pathways and has potential for the treatment of neuroblastoma.
['Nozawa|Akifumi|A|', 'Ozeki|Michio|M|', 'Matsuoka|Mikako|M|', 'Nakama|Mina|M|', 'Yasue|Shiho|S|', 'Endo|Saori|S|', 'Kawamoto|Norio|N|', 'Ohnishi|Hidenori|H|', 'Fukao|Toshiyuki|T|']
D000970:Antineoplastic Agents D045744:Cell Line, Tumor D049109:Cell Proliferation D015536:Down-Regulation D048049:Extracellular Signal-Regulated MAP Kinases D006801:Humans D009447:Neuroblastoma D009570:Nitriles D010766:Phosphorylation D051057:Proto-Oncogene Proteins c-akt D011728:Pyridones D018091:Receptors, AMPA
AMPAR antagonist AMPA receptor Pediatric oncology glutamate receptors molecular targeted therapy